Table 4.
Ocular and side effect characteristic of biological treatment mechanism groups.
| Variable | Group 1 N (%) | Group 2 N (%) | Group 3 N (%) | Group 4 N (%) | p value (χ2) |
|---|---|---|---|---|---|
| Past ocular history | 0.081 | ||||
| Cataract | 4 (40) | 5 (100) | 1 (33.3) | 1 (25) | |
| ERM | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
| CSR | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | |
| Side effects | 0.219 | ||||
| posterior, panuveitis) | 4 (40) (3, 0, 1) | 3 (60) (2, 1, 0) | 0 (0) (0, 0, 0) | 2 (50) (2, 0, 0) | |
| CSR-like | 3 (30) | (0) | 1 (33.3) | 1 (25) | |
| Dry eye | 2 (20) | 2 (40) | 0 (0) | 1 (12.5) | |
| Vitreitis | 2 (20) | 0 (0) | 0 (0) | 0 (0) | |
| CRAO | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
| CME | 1 (10) | 0 (0) | 0 (0) | 0 (0) | |
| Trichomegaly | 0 (0) | 0 (0) | 2 (66.6) | 1 (25) | |
| BRVO | 0 (0 | 1 (20) | 0 (0) | 0 (0) | |
| Treatment | 0.325 | ||||
| Intravitreal injection | 2 | 1 | 0 | 0 | |
| Topical | 5 | 4 | 0 | 3 | |
| Medical | 1 | 0 | 0 | 0 | |
| Surgical | 1 | 0 | 0 | 0 |
CSR, central serous retinopathy; CRAO, central retinal artery occlusion; CME, cystoid macular edema; BRVO, branch retinal vein occlusion.